- Saturday, December 13, 2025
- India +91 7982732466
- U.S +1 217 953 4020
- Info@Shingetsuresearch.com
Global Vaccines Market by Type (Monovalent Vaccines and Multivalent Vaccines), By Technology (Conjugate Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), By Disease Indication (Covid-19, Pneumococcal Disease, DTP, Influenza, HPV, Meningococcal Disease, Polio, Hepatitis, Rotavirus and Others), By Route of Administration (Intramuscular and Subcutaneous Administration and Oral Administration), By Patient Type (Pediatric Patients and Adult Patients), By Distribution Channel (Institutional Sales, Hospital Pharmacies, Retail Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa)
Global Vaccines Market Overview:
The global Vaccines Market is estimated to reach USD 127.2 billion by 2030, growing at a CAGR of 6.7% during the forecast period of 2022-2030. It was valued at USD 119.9 billion in 2022. Vaccines refer to biological products made from various types of pathogenic microorganisms for vaccination. The vaccine made with bacteria or Borrelia is also called a vaccine. Vaccines are two types, live vaccines, and dead vaccines—the live vaccines include BCG vaccine, polio vaccine, measles vaccine, and plague vaccine. The dead vaccines include pertussis vaccine, typhoid vaccine, meningococcal vaccine, and cholera vaccine. The production time varies from vaccine to vaccine, and some vaccines can take up to 22 months to produce one batch. The development of a vaccine is a complicated and lengthy process and is costly. Vaccination is the most economical and effective public health intervention to prevent and control infectious diseases. It is also an effective means for families to reduce the incidence of diseases and reduce medical costs.Global Vaccines Market Insights
The high prevalence of infectious diseases, increasing government support for vaccine development, and the rising focus on immunization projected to propel the growth of the global vaccines market in future periods. Moreover, the surge in demand for better healthcare infrastructure and growing awareness regarding the benefits of immunization will boost the global vaccines market size in the coming years. Additionally, the rising prevalence of several diseases along with the growing need to vaccinate children to prevent them from serious diseases will influence the global vaccines market in the forthcoming periods. In developing countries such as China and India, due to the steady increase in demand for vaccines, the strengthening of the public’s concept of immunization, and the government’s policy guidance and support, the vaccine market has developed and grown at a rapid rate. The increasing incidence of various infectious diseases and the expanding awareness about early disease diagnosis and prevention are estimated to drive the global vaccine industry in the next few years.Growth Driver
High Prevalence of Infectious Diseases
Infectious diseases are caused by pathogenic microorganisms like bacteria, viruses, parasites, or fungi. According to WHO, the burden of infectious diseases, including HIV, TB, malaria, hepatitis B, and neglected tropical diseases (NTDs) is higher in low-income countries than in high-income countries. Mortality rates attributed to unsafe water, unsafe sanitation, and lack of hygiene are also highest in low-income countries, as are mortality rates for road traffic injuries and unintentional poisoning.Growing Government Support for Vaccine Development
WHO started the implementation of the Global Vaccine Action Plan (GVAP), WHO’s strategic goals for vaccines is between 2015-2030. This plan promotes some objective such as the development of new vaccines such that it meets public health priorities and establish better rules and regulation for vaccines and delivery technologies that are of assured quality.Increasing Focus on Immunization Programs
WHO implemented a plan for immunization to be effective in preventing morbidity and mortality; every child should fully immunize. There are two ways to measure the efficiency of immunization, such as to measure immunization coverage by each vaccine. Firstly, comparing the number of doses given to the number of infants eligible to receive them and measure drop-out rates. Secondly, comparing the number of infants that started receiving immunizations to the number of infants who received all needed doses of vaccines.Type Segmental Analysis
Based on type, the global Vaccines market classified into Monovalent Vaccines and Multivalent Vaccines. The Monovalent Vaccines segment accounts for the largest share of the market in 2021, owing to the growing prevalence of diseases and upsurge in government and non-government initiatives to promote immunization. The Multivalent Vaccines segment will drive as it helps parents and healthcare providers perceived reduction in pain for the infant, fewer missed opportunities to vaccinate, convenience, and decreased costs for the parent.Technology Segmental Analysis
Based on technology, the global Vaccine market segregated into Conjugate Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugate Vaccines segment projected to dominate the market by 2030. It is attributed to growing government support and increasing company investments in conjugate vaccine development. The Recombinant Vaccines segment will influence by its application in animals for the prevention of diseases such as pneumonia, foot and mouth disease, septicemia, and pox disease.Disease Indication Segmental Analysis
Based on disease indication, the global vaccines market classified into Pneumococcal Disease, DTP, Influenza, HPV, Meningococcal Disease, Polio, Hepatitis, Rotavirus, and Others. The HPV segment estimated to generate maximum revenue in 2021, attributable to the surge in the incidence of cervical cancer coupled with growing awareness about preventive measures. The Pneumococcal Disease segment will grow by the upsurge in the incidence of pneumococcal disease along with growing government investments in pneumococcal vaccination programs.Route of Administration Segmental Analysis
Based on the route of administration, the global Vaccines market bifurcates into Intramuscular & Subcutaneous Administration and Oral Administration. Intramuscular & Subcutaneous Administration segment expected to grow with a higher rate owing to this mode of administration is associated with better immune response and a lower rate of injection site reactions.Patient Type Segmental Analysis
Based on patient type, the global Vaccines market bifurcates into Pediatric Patients and Adult Patients. Pediatric Patients segment likely to dominate the market by 2030, on account of the increasing awareness about vaccine-preventable diseases among children coupled with various governments’ numerous efforts to increase adult immunization rate.Distribution Channel Segmental Analysis
Based on the distribution channel, the global Vaccines market categorized into Institutional Sales, Hospital Pharmacies, Retail Pharmacies, and Others. Institutional Sales segment accounted for a higher market share in 2021 and maintain its dominance by 2030 as a result of institutional sales like hospitals has created stellar opportunities for growth of the market and provides dedicated sections for vaccination and treatment. Retail Pharmacies segment will boost attributable to the cost-effectiveness and readily availability of vaccines on pharmacy stores.Region Segmental Analysis
Based on geography, the global Vaccines market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America estimated to occupy the lion’s market share by 2030, owing to the rising government support for vaccine development and the high prevalence of infectious diseases in these regions. The Asia Pacific will drive attributed to the high incidence rate of infectious diseases, growing geriatric population base coupled with various initiatives undertaken by the governments to expand the provision of vaccines in these regions.Competitor Analysis
Companies such as GlaxoSmithKline plc, Pfizer, Inc., Sanofi Pasteur, Merck & Co., Inc., CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, AstraZeneca, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Panacea Biotec, Biological E, Bharat Biotech, Sinovac Biotech Ltd., Incepta Vaccine Ltd., Valneva SE, VBI Vaccines Inc., and PT Bio Farma are the key players in the Global Vaccines Market.Key Stakeholders
- Market research and consulting firms
- Industry associations
- Global Vaccines manufacturing firm
- Research organizations and consulting companies
- Organizations, associations, and alliances related to Vaccines
- Regulatory bodies
- Suppliers
- Retailers
The objective of the Research
- Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
- Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
- Market Trend and Economic Factors Analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
- Market Segmental Analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
- The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.
Market Modelling
By Type- Monovalent Vaccines
- Multivalent Vaccines
- Conjugate Vaccines
- Inactivated & Subunit Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Covid-19
- Pneumococcal Disease
- DTP
- Influenza
- HPV
- Meningococcal Disease
- Polio, Hepatitis
- Rotavirus
- Others
- Intramuscular and Subcutaneous Administration
- Oral Administration
- Pediatric Patients
- Adult Patients
- Institutional Sales
- Hospital Pharmacies
- Retail Pharmacies
- Others
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
More Related Reports:
Fabric Printing Machine Market
Report Content
- Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
- Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
- Executive Summary
- Market Insights
4.1. Supply Chain Analysis
4.2. Economic Factor Analysis
4.2.1. Drivers
4.2.2. Trends
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape
4.4. Competitors & Product Analysis
4.5. Regulatory Framework
4.6. Company market share analysis, 2022
4.7. Porter’s Five forces analysis
4.8. Price point analysis
4.9. New Investment Analysis
4.10. PESTEL Analysis
- Global Vaccines Market Overview
5.1. Market Size & Forecast,2017-2030
5.1.1. Demand
5.1.1.1. By Value (USD Billion)
5.2. Market Share & Forecast, 2017-2030
5.2.1. By Type
5.2.1.1. Monovalent Vaccines
5.2.1.2. Multivalent Vaccines
5.2.2. By Technology
5.2.2.1. Conjugate Vaccines
5.2.2.2. Inactivated & Subunit Vaccines
5.2.2.3. Live Attenuated Vaccines
5.2.2.4. Recombinant Vaccines
5.2.2.5. Toxoid Vaccines
5.2.3. By Disease Indication
5.2.3.1. Covid-19
5.2.3.2. Pneumococcal Disease
5.2.3.3. DTP
5.2.3.4. Influenza
5.2.3.5. HPV
5.2.3.6. Meningococcal Disease
5.2.3.7. Polio
5.2.3.8. Hepatitis
5.2.3.9. Rotavirus
5.2.3.10. Others
5.2.4. By Route of Administration
5.2.4.1. Intramuscular and Subcutaneous Administration
5.2.4.2. Oral Administration
5.2.5. By Patient Type
5.2.5.1. Pediatric Patients
5.2.5.2. Adult Patients
5.2.6. By Distribution Channel
5.2.6.1. Institutional Sales
5.2.6.2. Hospital Pharmacies
5.2.6.3. Retail Pharmacies
5.2.6.4. Others
5.2.7. By Region
5.2.7.1. North America
5.2.7.2. Europe
5.2.7.3. Asia-Pacific
5.2.7.4. South America
5.2.7.5. The Middle East & Africa
- North America Vaccines Market Overview
6.1. North America Vaccines Market Size & Forecast,2017-2030
6.1.1. Demand
6.1.1.1. By Value (USD Billion)
6.2. Market Share & Forecast, 2017-2030
6.2.1. By Type
6.2.1.1. Monovalent Vaccines
6.2.1.2. Multivalent Vaccines
6.2.2. By Technology
6.2.2.1. Conjugate Vaccines
6.2.2.2. Inactivated & Subunit Vaccines
6.2.2.3. Live Attenuated Vaccines
6.2.2.4. Recombinant Vaccines
6.2.2.5. Toxoid Vaccines
6.2.3. By Disease Indication
6.2.3.1. Covid-19
6.2.3.2. Pneumococcal Disease
6.2.3.3. DTP
6.2.3.4. Influenza
6.2.3.5. HPV
6.2.3.6. Meningococcal Disease
6.2.3.7. Polio
6.2.3.8. Hepatitis
6.2.3.9. Rotavirus
6.2.3.10. Others
6.2.4. By Route of Administration
6.2.4.1. Intramuscular and Subcutaneous Administration
6.2.4.2. Oral Administration
6.2.5. By Patient Type
6.2.5.1. Pediatric Patients
6.2.5.2. Adult Patients
6.2.6. By Distribution Channel
6.2.6.1. Institutional Sales
6.2.6.2. Hospital Pharmacies
6.2.6.3. Retail Pharmacies
6.2.6.4. Others
6.2.7. By Country
6.2.7.1. US
6.2.7.2. Canada
6.2.7.3. Mexico
6.2.8. Company Market Share (Top 3-5)
6.2.9. Economic Impact Study on North America Vaccines Market
- Europe Vaccines Market Overview
7.1. Europe Vaccines Market Size & Forecast,2017-2030
7.1.1. Demand
7.1.1.1. By Value (USD Billion)
7.2. Market Share & Forecast, 2017-2030
7.2.1. By Type
7.2.1.1. Monovalent Vaccines
7.2.1.2. Multivalent Vaccines
7.2.2. By Technology
7.2.2.1. Conjugate Vaccines
7.2.2.2. Inactivated & Subunit Vaccines
7.2.2.3. Live Attenuated Vaccines
7.2.2.4. Recombinant Vaccines
7.2.2.5. Toxoid Vaccines
7.2.3. By Disease Indication
7.2.3.1. Covid-19
7.2.3.2. Pneumococcal Disease
7.2.3.3. DTP
7.2.3.4. Influenza
7.2.3.5. HPV
7.2.3.6. Meningococcal Disease
7.2.3.7. Polio
7.2.3.8. Hepatitis
7.2.3.9. Rotavirus
7.2.3.10. Others
7.2.4. By Route of Administration
7.2.4.1. Intramuscular and Subcutaneous Administration
7.2.4.2. Oral Administration
7.2.5. By Patient Type
7.2.5.1. Pediatric Patients
7.2.5.2. Adult Patients
7.2.6. By Distribution Channel
7.2.6.1. Institutional Sales
7.2.6.2. Hospital Pharmacies
7.2.6.3. Retail Pharmacies
7.2.6.4. Others
7.2.7. By Country
7.2.7.1. Germany
7.2.7.2. UK
7.2.7.3. France
7.2.7.4. Italy
7.2.7.5. Rest of Europe
7.2.8. Company Market Share (Top 3-5)
7.2.9. Economic Impact Study on Europe Vaccines Market
- Asia-Pacific Vaccines Market Overview
8.1. Asia-Pacific Vaccines Market Size & Forecast,2017-2030
8.1.1. Demand
8.1.1.1. By Value (USD Billion)
8.2. Market Share & Forecast, 2017-2030
8.2.1. By Type
8.2.1.1. Monovalent Vaccines
8.2.1.2. Multivalent Vaccines
8.2.2. By Technology
8.2.2.1. Conjugate Vaccines
8.2.2.2. Inactivated & Subunit Vaccines
8.2.2.3. Live Attenuated Vaccines
8.2.2.4. Recombinant Vaccines
8.2.2.5. Toxoid Vaccines
8.2.3. By Disease Indication
8.2.3.1. Covid-19
8.2.3.2. Pneumococcal Disease
8.2.3.3. DTP
8.2.3.4. Influenza
8.2.3.5. HPV
8.2.3.6. Meningococcal Disease
8.2.3.7. Polio
8.2.3.8. Hepatitis
8.2.3.9. Rotavirus
8.2.3.10. Others
8.2.4. By Route of Administration
8.2.4.1. Intramuscular and Subcutaneous Administration
8.2.4.2. Oral Administration
8.2.5. By Patient Type
8.2.5.1. Pediatric Patients
8.2.5.2. Adult Patients
8.2.6. By Distribution Channel
8.2.6.1. Institutional Sales
8.2.6.2. Hospital Pharmacies
8.2.6.3. Retail Pharmacies
8.2.6.4. Others
8.2.7. By Country
8.2.7.1. India
8.2.7.2. Japan
8.2.7.3. Australia
8.2.7.4. Rest of Asia Pacific
8.2.8. Company Market Share (Top 3-5)
8.2.9. Economic Impact Study on Asia Pacific Vaccines Market
- South America Vaccines Market Overview
9.1. South America Vaccines Market Size & Forecast,2017-2030
9.1.1. Demand
9.1.1.1. By Value (USD Billion)
9.2. Market Share & Forecast, 2017-2030
9.2.1. By Type
9.2.1.1. Monovalent Vaccines
9.2.1.2. Multivalent Vaccines
9.2.2. By Technology
9.2.2.1. Conjugate Vaccines
9.2.2.2. Inactivated & Subunit Vaccines
9.2.2.3. Live Attenuated Vaccines
9.2.2.4. Recombinant Vaccines
9.2.2.5. Toxoid Vaccines
9.2.3. By Disease Indication
9.2.3.1. Covid-19
9.2.3.2. Pneumococcal Disease
9.2.3.3. DTP
9.2.3.4. Influenza
9.2.3.5. HPV
9.2.3.6. Meningococcal Disease
9.2.3.7. Polio
9.2.3.8. Hepatitis
9.2.3.9. Rotavirus
9.2.3.10. Others
9.2.4. By Route of Administration
9.2.4.1. Intramuscular and Subcutaneous Administration
9.2.4.2. Oral Administration
9.2.5. By Patient Type
9.2.5.1. Pediatric Patients
9.2.5.2. Adult Patients
9.2.6. By Distribution Channel
9.2.6.1. Institutional Sales
9.2.6.2. Hospital Pharmacies
9.2.6.3. Retail Pharmacies
9.2.6.4. Others
9.2.7. By Country
9.2.7.1. Brazil
9.2.7.2. Argentina
9.2.7.3. Rest of South America
9.2.8. Company Market Share (Top 3-5)
9.2.9. Economic Impact Study on South America Vaccines Market
- The Middle East & Africa Vaccines Market Overview
10.1. The Middle East & Africa Vaccines Market Size & Forecast,2017-2030
10.1.1. Demand
10.1.1.1. By Value (USD Billion)
10.2. Market Share & Forecast, 2017-2030
10.2.1. By Type
10.2.1.1. Monovalent Vaccines
10.2.1.2. Multivalent Vaccines
10.2.2. By Technology
10.2.2.1. Conjugate Vaccines
10.2.2.2. Inactivated & Subunit Vaccines
10.2.2.3. Live Attenuated Vaccines
10.2.2.4. Recombinant Vaccines
10.2.2.5. Toxoid Vaccines
10.2.3. By Disease Indication
10.2.3.1. Covid-19
10.2.3.2. Pneumococcal Disease
10.2.3.3. DTP
10.2.3.4. Influenza
10.2.3.5. HPV
10.2.3.6. Meningococcal Disease
10.2.3.7. Polio
10.2.3.8. Hepatitis
10.2.3.9. Rotavirus
10.2.3.10. Others
10.2.4. By Route of Administration
10.2.4.1. Intramuscular and Subcutaneous Administration
10.2.4.2. Oral Administration
10.2.5. By Patient Type
10.2.5.1. Pediatric Patients
10.2.5.2. Adult Patients
10.2.6. By Distribution Channel
10.2.6.1. Institutional Sales
10.2.6.2. Hospital Pharmacies
10.2.6.3. Retail Pharmacies
10.2.6.4. Others
10.2.7. By Country
10.2.7.1. Saudi Arabia
10.2.7.2. UAE
10.2.7.3. South Africa
10.2.7.4. Rest of the Middle East & Africa
10.2.8. Company Market Share (Top 3-5)
10.2.9. Economic Impact Study on Middle East & Africa Vaccines Market
- Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. GlaxoSmithKline plc
11.7.2. Pfizer, Inc.
11.7.3. Sanofi Pasteur
11.7.4. Merck & Co., Inc.
11.7.5. CSL Limited
11.7.6. Emergent BioSolutions, Inc.
11.7.7. Johnson & Johnson
11.7.8. AstraZeneca
11.7.9. Serum Institute of India Pvt. Ltd.
11.7.10. Bavarian Nordic
11.7.11. Mitsubishi Tanabe Pharma Corporation
11.7.12. Daiichi Sankyo Company, Limited
11.7.13. Panacea Biotec
11.7.14. Biological E Ltd
11.7.15. Bharat Biotech
11.7.16. Sinovac Biotech Ltd.
11.7.17. Incepta Vaccine Ltd.
11.7.18. Valneva SE
11.7.19. VBI Vaccines Inc.
11.7.20. PT Bio Farma
11.7.21. Other Prominent Players
Frequently Asked Questions (FAQ)
Vaccines refer to biological products made from various types of pathogenic microorganisms for vaccination. The vaccine made with bacteria or Borrelia is also called a vaccine.
The global Vaccines Market is estimated to reach USD 127.2 billion by 2030, growing at a CAGR of 6.7% during the forecast period of 2022-2030. It was valued at USD 119.9 billion in 2022.
Companies such as GlaxoSmithKline plc, Pfizer, Inc., Sanofi Pasteur, Merck & Co., Inc., CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, AstraZeneca, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Panacea Biotec, Biological E, Bharat Biotech, Sinovac Biotech Ltd., Incepta Vaccine Ltd., Valneva SE, VBI Vaccines Inc., and PT Bio Farma are the key players in the Global Vaccines Market.
The increasing incidence of various infectious diseases and the expanding awareness about early disease diagnosis and prevention are estimated to drive the global vaccine industry.
